1 / 64

Yuh-Feng Lin MD

Yuh-Feng Lin MD. Acute Complications of Hemodialysis. Director of Internal Medicine, Shuang-Ho Hospital,Taipei Medical University; professor, Tri-Service General Hospital. Yuh-Feng Lin M.D. ★. Intradialytic hypotension.

svea
Download Presentation

Yuh-Feng Lin MD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Yuh-Feng Lin MD

  2. Acute Complications of Hemodialysis Director of Internal Medicine, Shuang-Ho Hospital,Taipei Medical University; professor, Tri-Service General Hospital Yuh-Feng Lin M.D.

  3. ★ Intradialytic hypotension • Definition: A decrease in systolic BP ≥20 mm Hg or a decrease in MAP ≥ 10 mm Hg associated with symptoms. • Complication: cardiac arrhythmias, coronary and/or cerebral ischemic events • Long-term side effects: volume overload due to suboptimal ultrafiltration, LVH, and interdialytic hypertension K-DOQI guildline

  4. Risk Factors of Dialysis Hypotension • A third of dialysis patients • Low body mass • Poor nutritional status and hypoalbuminemia • Severe anemia • Advanced age (Age > 65 years old) • Cardiovascular disease • Large interdialysis weight gain • Low blood pressure (predialysis systolic BP <100 mm Hg)

  5. Etiology of Dialysis Hypotension (I) • Excessive rate and degree of ultrafiltration • Inappropriate peripheral venodilation • Autonomic dysfunction • Inadequate vasoconstrictor secretion

  6. Etiology of Dialysis Hypotensoin (II) • Acetate dialysate • Low calcium dialysate • Eat shortly before dialysis • Antihypertensive medications • LV dysfunction

  7. PATHOGENESIS MEDIATORS PATIENT PATHOPHYSIOLOGY Heart Disease CARDIAC OUTPUT Volume Ultrafiltration Vascular Disease Osmolality Fall Vasopressors Autonomic Dysfunction Vasodilatator Warm Dialysate PERIPHERAL RESISTANCE Hormonal Dysfunction Cell Dysfunction Bio-incom- patibility Medications Complement Activation, Cytokine release Endotoxin Sepsis Infection HYPOTENSiON Acetate Infusion Hypoxemia Vasovagal stim.

  8. Table. Results of four tests of autonomic function in normotensive and hypotensive patients on maintenance hemodialysis Before Dialysis After Dialysis Test Normotensive Hypotensive Normotensive Hypotensive Orthostasis (standing up) ∆SBP (mmHg) -3.7 ± 2.7 -14.1 ± 2.6* -6.0 ± 2.7 -16.0± 3.1† ∆DBP (mmHg) -4.6 ± 1.6 -11.5 ± 1.4* -4.3 ± 1.7 -10.0 ± 1.7† 30:15 ratio (normal ≥ 1.04) 1.045 ± 0.02 1.023 ± 0.014 1.036 ± 0.015 1.023 ± 0.011 Valsalva quotient (normal ≥ 1.21) 1.060 ± 0.025 1.024 ± 0.014 1.102 ± 0.028 1.012± 0.029† Sustained handgrip (normal ≥15) ∆DBP (mmHg)5.8 ± 2.3 7.1 ± 0.7 7.2 ± 1.1 6.8 ± 0.7 Cutaneous cold ∆SBP (mmHg) 6.8 ± 1.4 7.1 ± 1.2 5.9 ± 1.0 5.6 ± 0.8 ∆DBP (mmHg)5.1 ± 1.3 4.9 ± 1.4 4.5 ± 0.9 4.4 ± 0.7 Lin YF, Wang JY et al., ASAIO 39:946-953, 1993.

  9. BV (%)  cGMP (pmol/ml)  Fig. Correlation between changes in blood volume and plasma cGMP throughout HD. Wann GL. Lin YF. ASAIO 44:M569, 1998.

  10. Plasma NO2- + NO3- (mM/l) Fig. Plasma levels of nitrite and nitrate in hypotensive and normotensive patients on hemodialysis. Lin SH. ASAIO J 42:M895, 1996.

  11. Accurate Estimation of Dry Weight • cGMP, ANP • IVCD • Continuous monitoring of BV • Bioimpedence ECF/TBW

  12. Prevention and Management of Dialysis Hypotension (I) • Limiting sodium intake • Minimize interdialytic weight gain by education • Blood sugar control • Slow ultrafiltration • Sodium modeling • Raise dialysate calcium • Lower dialysate temperature

  13. Prevention and Management of Dialysis Hypotension (II) • Switch to CAPD • Hyperoncotic albumin • Nasal oxygen • Mannitol infusion

  14. Prevention and Management of Dialysis Hypotension (III) • L-Carnitine therapy • Sertraline • Midodrine • Blood transfusion or erythropoietin therapy • Volume expansion • Vasoconstrictor

  15. p < 0.005 Number of Hypotensive episodes Fig. Number of hypotensive episodes per hemodialysis session in the sertraline and pre-sertraline periods. Dheenan S. AJKD 31:624, 1998.

  16. Figure. Serial changes in MAP HD before ( ) and after ( )midodrine therapy. YF Lin et al. Am J Med Sci 2003;325:256-61.

  17. Conclusion and clinical application • Midodrine improves chronic hypotensin in HD patients by modulating autonomic function and its direct effects on peripheral vessels.

  18. Table. Carnitine levels in patients with (n=8) and without (n=23) intra-dialytic hypotension Without hypotension With hypotension Total carnitine (mml/l) 27.0 ± 2.7 18.4 ± 2.2* Free carinitine (mmol/l) 18.8 ± 2.0 10.9 ± 1.7** Acyl/free carnitine ratio 0.58 ± 0.06 0.78 ± 0.15 Values are mean ± SEM, * p < 0.05, ** p < 0.01 vs without hypotension Riley S. Clin Nephrol 48:392, 1997.

  19. Hypoxemia • Alkali attenuate hyperventilation • Acetate dialysate • Complement activation • Pulmonary leukosequestration • Actin polymerization • Biocompatible hollow fiber

  20. Muscle Cramps • 35-86%of hemodialysis patients • Lower extremities • Mechanisms: Rapid ultrafiltration, Intradialytic hypotension, tissue hypoxia • Treatment: Quinine, Vit E, L-carnitine, Creatine monohydrate, Sodium modeling, hypertonic solution

  21. ★

  22. Acute Allergic Reaction • First use syndrome • Burning retrosternal pain • Diffuse heat, cold perspiration, urticaria, pruritus, laryngeal strider, bronchospasm, loss of consciousness • Polyurethane function as a reservoir for ethylene oxide

  23. ** * Serum C3a (ng/ml) ** Fig. Comparisons of serum C3a levels during hemodialysis procedure with different dialysis membrane. (* p< 0.05, ** p<0.01 vs baseline)

  24. * * WBC (/cumm) ** Fig. Comparisons of WBC levels during hemodialysis procedure with different dialysis membrane. (* p< 0.05, ** p<0.01 vs baseline)

  25. TNF-a (pg/ml/2 x 106 monocytes) Fig. Comparisons of TNF-a production by zymoxan-stimulationed Monocytes between Cuprophan and PMMA hollow fiber before, at the 15th minute of and at the end of dialysis. NC= Normal control. ** p<0.01 between two hollow fibers, +++ p<0.001 among three time periods. YF Lin. Am J Nephorl 16:293, 1996.

  26. Table. Clinical relevance of cytokine production in hemodialysis patients Acute Chronic Fever Anemia Sleep disorders Bone disease Hypotension Malnutrition Immunological dysfunction Pertosa G KI 58 suppl 76:S104, 2000.

  27. Fig. Relationship between interleukin-6 (IL-6) production by peripheral blood mononuclear cells (PBMC) and erythropoietin (EPO) requirements in 34 hemodialysis subjects (r=0.384, p=0.039) Goicoechea M KI 54:1337, 1998.

  28. Serum b2 microglobulin (mg/L) * * * * Fig. Comparisons of serum b2M during hemodialysis procedure with different dialysis membrane. (* p< 0.05 vs baseline)

  29. ★ Uremic Pruritus (I) • 50-90%of dialysis patients • Risk: male, high serum BUN, Ca, P, β2-microglobulin, duration of dialysis • Diagnositc criteria

  30. ★ Pathogenesis • Pruritogenic substancemast cell release histamine, IL-2, …cascade of nerve conduction to induce in perception of itch

  31. ★ Causes of itching in ESRD

  32. ★ Uremic Pruritus (II) Topical treatment (a) Skin emollients (b) Capsaicin (c) Topical steroids Physical treatment (a) Phototherapy (b) Acupuncture (c) Sauna Systemic treatment (a) Low-protein diet (b) Primrose oil (c) Lidocaine and mexilitine (d) Opioid antagonists (e) Activated charcoal (f) Cholestyramine (g) Serotonin antagonists (h) Parathyroidectomy (i) Nalfurafine • Optimize the dialysis dose • Treat anemia • Treat 2nd hyperparathyroidism • Ultraviolet B phototherapy • Topical emollients • Capsaicin • Antihistamine • Anti-serotonin agents

  33. Table. Degree of pruritus on capsaicin therapy Degree of pruritus None Mild Moderate Severe Before treatment 0 0 8 9 After treatment * 5 9 1 2 8 weeks postreatment 4 5 5 3

  34. ★ κ-opoid receptor agonist-Nalfurafine

  35. ★ Arrhythmia (I) • 30-48%of dialysis patients • Risk factor: ▲Compromised myocardium: CAD, Intermyocardiocytic fibrosis, Pericarditis ▲ Increased QT interval or dispersion

  36. ★ Arrhythmia (II) ▲ Electrolyte imbalance: hypokalemia, hyperkalemia, hypercalcemia, hypermagnesemia ▲ Anemia ▲ Increased LV mass ▲ Advanced age ▲ Acetate dialysate

  37. 500 P < 0.001 450 400 350 0 Contol (n=30) HD (n=42) Fig. Distribution of QTc values among hemodialysis patients and controls. The mean value of QTc was significantly increased in hemodialysis patients (432.6 ± 24.9 ms) compared controls (402.0 ± 21.0 ms) (p<0.01) Suzuki R. Clin Nephrol 49:240, 1998.

  38. Table. Independent predictors of QTc interval by multivariate stepwise regression analysis Variable Coefficient Standard error T value P value Diabetes mellitus 25.773 6.203 4.155 0.0002 Ejection fraction -111.18 42.546 -2.613 0.0127 (Constant) 494.6 28.929 17.097 Independent factor: QTc interval R2 = 0.497 Suzuki R. Clin Nephrol 49:240, 1998.

  39. Results of 24-Hour Holter ECG Monitoring Arrhythmias Seen No. of Tapes (%) Ventricular ectopic beats (> 20/hr) 15 (24) Ventricular ectopic beats (> 100/hr) 2 (3) Episodes of ventricular tachycardia 5 (8) Epidoses of supraventricular tachycardia 2 (3) Episodic atrial fibrillation 7 (11) Heart block (intermittent) 1 (1.6) Jassal SV AJKD 30:219, 1997.

  40. Bleeding During Dailysis (I) • Platelet dysfunction • Impaired dense granule release of ATP and serotonin • Reduced synthesis of thromboxane A2 • Elevated platelet cytosolic cAMP and calcium • Impaired aggregation response

  41. Bleeding During Dialysis (II) • Altered adhesive fibrinogen and vWf • Impaired fibrinogen receptor (GPIIbIIIa) function • Uremic toxin or inhibitors • Erythropoietin augments GPIIbIIIa

  42. Bleeding During Dialysis (III) • Pack RBC • Cryoprecipitate, FFP(VIII/vWF) • dDAVP • Estrogen

  43. Air Embolism • 1 ml/kg air may be fatal • Occlude RV outflow tract and pulmonary vascular bed • Thromboxane B2, endothelin • Trendelenburg position with left side down • Withdrawal of air from RA • Hyperbaric oxygen

  44. ★ Dialysis Pericarditis I • Uremic pericarditis: pericarditis before RRT or within 8 weeks of its initiation. • Dialysis pericarditis: ≥ 8 weeks after initiation of RRT. • Incidence of dialysis pericarditis: 2-12% • Etiology: inadequate dialysis, volume overload, infection, autoimmune, drugs

  45. Dialysis Pericarditis II • Precordial pain, hypotension, dyspnea, fever, weight gain • Heparin free dialysis • Intensive dialysis • NSAID • Subxiphoid pericardiostomy

  46. Dialysis Disequilibrium (I) • Headache, vomiting, seizure, delirium • Rapid correction of marked azotemia • Cerebral swelling • Reverse urea effect • Acidosis of the CSF

  47. Dialysis Disequilibrium (II) • Inefficient dialysis • Shorten the duration • Lower dialyzer blood flow • Less efficient dialyzer • Osmotic agents, high sodium • IV diazepam

  48. Metabolic Disorders • Metabolic alkalosis • Sodium citrate • Falty delivery of a buffer base • Fluoride poisoning • Acute cupper intoxication

  49. Sodium Disorders • Conductivity limits are not adjusted • Water intoxication • Hyperkalemia • Metabolic acidosis • Correction of hyponatremia • Drink water, 5% G/W for hypernatremia

  50. Hypokalemia • Loss into dialysate, alkali therapy • Renal or extrarenal losses • Arrhythmia, hypotension, fatigue, weakness, paralysis • CAD, digitalis, hypercalcemia, hypomagnesemia, meta alkalosis • Adjust dialysate potassium and buffer

More Related